|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sheng A, Zhou P, Ye Y, Sun K and Yang Z:
Diagnostic efficacy of CT radiomic features in pulmonary invasive
mucinous adenocarcinoma. Scanning. 2022(5314225)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xu X, Shen W, Wang D, Li N, Huang Z, Sheng
J, Rucker AJ, Mao W, Xu H and Cheng G: . Clinical features and
prognosis of resectable pulmonary primary invasive mucinous
adenocarcinoma. Transl Lung Cancer Res. 11:420–431. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Butt YM and Allen TC: The demise of the
term bronchioloalveolar carcinoma. Arch Pathol Lab Med.
139:981–983. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Read WL, Page NC, Tierney RM, Piccirillo
JF and Govindan R: The epidemiology of bronchioloalveolar carcinoma
over the past two decades: Analysis of the SEER database. Lung
Cancer. 45:137–142. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Oktay E, Oflazoglu U, Varol Y, Tanriverdi
O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, et
al: The prognostic role of thyroid transcription factor-1 in lung
adenocarcinoma. J Cancer Res Ther. 16:737–744. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gardiner N, Jogai S and Wallis A: The
revised lung adenocarcinoma classification-an imaging guide. J
Thorac Dis. 6:537–546. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Moser L, Kegler K, Precht C and Zanolari
P: Bronchioalveolar carcinoma in an adult alpaca (Vicugna pacos).
BMC Vet Res. 15(139)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
He Y, Huang H, Xu M, Fu Z, Zhang X, Chen X
and Guo W: The effect of afatinib in a pretreated patient with
invasive mucinous adenocarcinoma of the lung harboring HER2 YVMA
insertion: A case report. Transl Cancer Res. 11:1819–1823.
2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chi K, Sun W, Yang X, Wu J, Wang H, Liu X,
Mao L, Zhou L, Huang X and Lin D: A prognostic classification based
on the International Association for the Study of Lung Cancer
histologic grading and immunoscore in KRAS-mutant invasive
non-mucinous adenocarcinoma. Thorac Cancer. 13:1050–1058.
2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kimura S, Onishi I and Kobayashi M: A rare
case of esophageal metastasis of invasive mucinous adenocarcinoma
of the lung. ACG Case Rep J. 9(e00857)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen X, Zhao Y, Wang D, Lin Y, Hou J, Xu
X, Wu J, Zhong L, Zhou Y, Shen J, et al: The
HNF4α-BC200-FMR1-positive feedback loop promotes growth and
metastasis in invasive mucinous lung adenocarcinoma. Cancer Res.
81:5904–5918. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang X, Qiao W, Kang Z, Pan C, Chen Y, Li
K, Shen W and Zhang L: CT features of stage IA invasive mucinous
adenocarcinoma of the lung and establishment of a prediction model.
Int J Gen Med. 15:5455–5463. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhu D, Zhang Q, Rui Z and Xu S: Pulmonary
invasive mucinous adenocarcinoma mimicking pulmonary actinomycosis.
BMC Pulm Med. 22(181)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mir E, Sareen R, Kulshreshtha R and Shah
A: Bronchioloalveolar cell carcinoma presenting as a ‘non-resolving
consolidation’ for two years. Pneumonol Alergol Pol. 83:208–211.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Narahari NK, Uppin SG, Kapoor A, Stalin BJ
and Paramjyothi GK: Invasive mucinous adenocarcinoma of the lung in
a 19-year-old female. Asian Cardiovasc Thorac Ann. 26:635–639.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nie K, Nie W, Zhang YX and Yu H: Comparing
clinicopathological features and prognosis of primary pulmonary
invasive mucinous adenocarcinoma based on computed tomography
findings. Cancer Imaging. 19(47)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kim DH, Bae SY, Na KJ, Park S, Park IK,
Kang CH and Kim YT: Radiological and clinical features of
screening-detected pulmonary invasive mucinous adenocarcinoma.
Interact Cardiovasc Thorac Surg. 34:229–235. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang T, Yang Y, Liu X, Deng J, Wu J, Hou
L, Wu C, She Y, Sun X, Xie D and Chen C: Primary invasive mucinous
adenocarcinoma of the lung: prognostic value of CT imaging features
combined with clinical factors. Korean J Radiol. 22:652–662.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Horiguchi T, Yanagi S, Tomita M, Maeda R,
Uto K, Shigekusa T, Tsubouchi H, Matsumoto N and Nakazato M: A case
of bilateral invasive mucinous adenocarcinoma of the lung with
severe productive cough and dyspnea successfully treated with
palliative lung lobectomy. Respir Med Case Rep.
32(101368)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kadota K, Yeh YC, D'Angelo SP, Moreira AL,
Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, et al:
Associations between mutations and histologic patterns of mucin in
lung adenocarcinoma: Invasive mucinous pattern and extracellular
mucin are associated with KRAS mutation. Am J Surg Pathol.
38:1118–1127. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Boland JM, Maleszewski JJ, Wampfler JA,
Voss JS, Kipp BR, Yang P and Yi ES: Pulmonary invasive mucinous
adenocarcinoma and mixed invasive mucinous/nonmucinous
adenocarcinoma-a clinicopathological and molecular genetic study
with survival analysis. Hum Pathol. 71:8–19. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cha YJ, Kim HR, Lee HJ, Cho BC and Shim
HS: Clinical course of stage IV invasive mucinous adenocarcinoma of
the lung. Lung Cancer. 102:82–88. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shim HS, Kenudson M, Zheng Z, Liebers M,
Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS and Iafrate AJ:
Unique genetic and survival characteristics of invasive mucinous
adenocarcinoma of the lung. J Thorac Oncol. 10:1156–1162.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Nakajima EC, Drezner N, Li X,
Mishra-Kalyani PS, Liu Y, Zhao H, Bi Y, Liu J, Rahman A, Wearne E,
et al: FDA approval summary: Sotorasib for KRAS G12C-mutated
metastatic NSCLC. Clin Cancer Res. 28:1482–1486. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Frontline promise for
Adagrasib-Pembrolizumab combination. Cancer Discov.
13(OF2)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mazieres J, Drilon A, Lusque A, Mhanna L,
Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et
al: Immune checkpoint inhibitors for patients with advanced lung
cancer and oncogenic driver alterations: results from the
IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nakagomi T, Goto T, Hirotsu Y, Shikata D,
Yokoyama Y, Higuchi R, Otake S, Amemiya K, Oyama T, Mochizuki H and
Omata M: Genomic characteristics of invasive mucinous
adenocarcinomas of the lung and potential therapeutic targets of
B7-H3. Cancers. 10:2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xu X, Li N, Wang D, Chen W and Fan Y:
Clinical relevance of PD-L1 expression and CD8+ T cells'
infiltration in patients with lung invasive mucinous
adenocarcinoma. Front Oncol. 11(683432)2021.PubMed/NCBI View Article : Google Scholar
|
